[
    [
        {
            "time": "2023-10-07",
            "original_text": "国产白血病新药！复星医药FN-1501获美国FDA授予孤儿药资格认定，治疗急性髓性白血病(AML)",
            "features": {
                "keywords": [
                    "复星医药",
                    "FN-1501",
                    "美国FDA",
                    "孤儿药资格认定",
                    "急性髓性白血病",
                    "AML"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国产白血病新药！复星医药FN-1501获美国FDA授予孤儿药资格认定，治疗急性髓性白血病(AML)",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]